SciSparc partners with Clearmind to develop psychedelic therapies

• SciSparc (NASDAQ:SPRC) said it had collaborated with Clearmind Medicine (OTCPK:CMNDF) to explore the development of psychedelic-based therapies.
• The companies, which have begun the collaboration with a joint pre-clinical study, said the psychedelic-centric drug candidates will target mental health-related diseases.
• According to the Market Digits, the psychedelics sector could be worth more than $10 billion by 2027, the company said.